AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
Acquisition provides access to next-generation T-cell receptor therapies with promising potential for targeting solid tumours.AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. With a shared goal of bringing cell therapies to patients with solid tumours, Neogene’s expertise in TCR-T discovery, development and manufacturing will